SURGERY FEATURES IN THE TREATMENT OF PATIENTS WITH HER2-neu POSITIVE BREAST CANCER
DOI:
https://doi.org/10.32471/oncology.2663-7928.t-22-1-2020-g.8568Keywords:
breast cancer, HER2-neu positive molecular subtype, neoadjuvant chemo-targeted therapy, organ-saving surgeryAbstract
Aim: based on author’s clinical observation and data from the scientific literature, to analyze direct results of systemic neoadjuvant chemo-targeted therapy (NACTT) (general tumor response) in patients with HER2-neu positive breast cancer (BC) and to demonstrate feasibility of conservative surgery for BC in this group of patients. Object and methods: medical records of patients with BC stages T1N0M0 (3), T2N0M0 (2), T2N1M (4), T2N2M0 (1) were analyzed. Five patients were diagnosed with luminal B (ER/PR+, Her2-neu+++) molecular subtype of breast cancer, in 5 others — HER2-neu positive subtype with negative hormone receptors (ER/PR-, Her2-neu+++). Seven patients received NACTT. Five patients underwent radical sectoral resections with axillary lymphadenectomy of I–II levels. The others underwent Madden mastectomy. The observation period is 1–7 years. Results: in most of the patients, systemic NACTT has been shown to result in complete therapeutic pathomorphosis (pCR) of both breast tumors and regional lymph nodes (ypT0 ypN0 (0/0), LVI0, Pn0, R0). Preoperative ultrasound, mammography, or CT scans can diagnose complete «visual» regression of breast tumors, which coincides with the morphological data of tumor devitalization. Under these conditions, organ-saving surgery should be preferred to mastectomy. Conclusions: in patients with HER2-neu positive BC under the condition of «visual» regression of tumor after NACTT, surgery intervention is advisable to be limited to sectoral resection of the breast with sentinel lymph node biopsy, or level I–II lymph node dissection, or so-called targeted axillary dissection (TAD). In case of the patient’s refusal of surgery, it is necessary to carry out active follow-up (ultrasound, mammography, MRI, CT) and to continue the planned systemic or endocrine therapy.
References
Caudle AS, Yang WT, Krishnamurthy S, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol 2016; 34(10): 1072–8.
Chang H.R. Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer. Cancer 2010; 15: 2856–67.
De Los Santos JF, Cantor A, Amos KD, et al. Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017. Cancer 2013; 119(10): 1776–83.
Durgan DM, Mitchell K, Seedman S, Bishop J. Axillary lymph node management in the era of neo-adjuvant chemotherapy, neo-endocrine treatment, and targeted axillary dissection. 20th Annual Meeting of the American Society of Breast Surgeons, April 30–May 5 2019, Dallas; Poster ID: 556984. 1
Hamy-Petit AS, Belin L, Bonsang-Kitzis H, et al. Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort. Br J Cancer 2016; 114: 44–52.
Kuerer HM, Vrancken Peeters MTFD, Rea DW, et al. Nonoperative management for invasive breast cancer after neoadjuvant systemic therapy: conceptual basis and fundamental international feasibility clinical trials. Ann Surg Oncol 2017; 24: 2855–62.
Sun SX, van la Parra R, Rauch GM, et al. Patient selection for clinical trials eliminating surgery for HER2-positive breast cancer treated with neoadjuvant systemic therapy. Ann Surg Oncol 2019; 26: 3071–9.
Tanioka M, Sasaki M, Shimomura A, et al. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status. The Breast 2014; 23: 466–72.
Untch M, Rezai M, Loibl S, et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol 2010; 28(12): 2024–31.
von Minckwitz G, Untch M, Blohmer J-U, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012; 30(15): 1796–804.
Wang J, Xu B. Targeted therapeutic options and future perspectives for HER2-positive breast cancer. Signal Transduction and Targeted Therapy 2019; 4: 34.
